Loading…
← CockpitCompetitor Analysis › 688236.SS Beijing Chunlizhengda Medical Instruments Co., Ltd. Class AOpen in the cockpit ↗

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class A688236.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum neutral 52
Mkt cap
$618M
US dollars, full cap
Free float
54%
of shares outstanding
$/day
$5.07M
20-day average traded
Fwd P/E
17.4×
forward earnings
ROIC−WACC
+16.5 pp
WACC 8.2%
Hurdle
-11 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · CNYCN¥12.45
1D-2.4%
1W-6.7%
1M-4.4%
3M-17.3%
6M-27.4%
YTD-45.6%
1Y-55.6%
ATR %4.0%
52w lowhigh57.3% off high

What Beijing Chunlizhengda Medical Instruments does

Employees: 1,078

Beijing Chunlizhengda Medical Instruments at a glance

Size Beijing Chunlizhengda Medical Instruments (688236.SS) is a China Health Care company (Medical Specialties) with a market value of $618M, the 3178th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.45 on 18 Nov 2026.

Performance Over six months the shares fell 27.4%, against -6.6% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 19 in its peer set.

Growth Revenue fell 13.1% over the last twelve months (peer median +16.2%); the operating margin is 30.6% (peer median 7.5%).

Valuation It trades at 17.4× forward earnings against a peer median of 26.0× (5th cheapest of 14).

Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 16.5 points above its cost of capital (8.2% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 94688236.SS 74
Six months, rebased to 100: Beijing Chunlizhengda Medical Instruments against the median of its 20 peers (local-currency closes).

Beijing Chunlizhengda Medical Instruments financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥916MCN¥1.04BCN¥800MCN¥1.20BCN¥1.19B
Revenue growth—+30%-33%0%—
Gross profitCN¥600MCN¥657MCN¥508MCN¥842MCN¥886M
EBITDAn/aCN¥308MCN¥125MCN¥292MCN¥307M
Net incomeCN¥270MCN¥273MCN¥125MCN¥278MCN¥308M
Free cash flowCN¥322MCN¥361M-CN¥30.4MCN¥501MCN¥43.3M
Capital expenditureCN¥42.2MCN¥59.1MCN¥49.2MCN¥33.2MCN¥24.9M
Total debtCN¥2.39MCN¥3.78MCN¥919,036CN¥12.8MCN¥18.3M

Quarterly statements and history in the cockpit →

Beijing Chunlizhengda Medical Instruments competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%XVIVO4728NANMEDISGHT1789TCMD300314OBIOQDELSNT300326300952PACB301235603122688236.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing Chunlizhengda Medical Instruments is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%50×100×XVIVONANMEDI1789TCMD688581300314QDELSNT300326300952301235002876688236.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing Chunlizhengda Medical Instruments is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%XVIVO4728NANMEDI1789TCMD688581SNT300326002876688236.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Beijing Chunlizhengda Medical Instruments is the large dot.

Beijing Chunlizhengda Medical Instruments competitors and peer comparison

How Beijing Chunlizhengda Medical Instruments compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing Chunlizhengda Medical Instruments against its 20 peers (data as of 18 Nov 2026)
Measure688236.SSPeer medianRank in peer set
1-month return-4.4%-3.4%9th lowest of 19
6-month return-27.4%-6.6%5th lowest of 19
Distance from 52-week high-57.3%-30.1%5th lowest of 20
Revenue growth (TTM)-13.1%+16.2%4th lowest of 20
Operating margin30.6%7.5%3rd highest of 20
Forward P/E17.4×26.0×5th cheapest of 14
Growth the price implies (Req g, 7 yrs)-8.5%3.5%2nd least demanding of 11
Growth delivered (Del g)+2.2%+14.3%2nd lowest of 11
Hurdle (Req g minus delivered)-10.7 pp-9.8 pp6th least demanding of 11
ROIC minus cost of capital+16.5 pp-0.2 pp4th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Beijing Chunlizhengda Medical Instruments 688236.SSChina$618M-27%-13%31%17.4×-8.5%+2.2%
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%53.1×35.9%+35.2%
SunMax Biotechnology 4728.TWOTaiwan$630M0%+19%51%n/a-2.6%+18.8%
Nanosonics NAN.AXAustralia$599M-4%+3%7%98.6×35.3%+6.7%
Medistim MEDI.OLNorway$599M+32%+19%29%31.8×-1.2%+14.5%
Sight Sciences SGHTUnited States$599M+122%+16%-30%n/an/an/a
Sahajanand Medical Technologies SMT.NSIndia$595Mn/an/an/an/an/an/a
AK Medical 1789.HKHong Kong$642M-23%+16%26%10.5×-11.5%+6.7%
vVARDIS VVVVUnited States$594Mn/a+148%-72%n/an/an/a
Tactile Systems Technology TCMDUnited States$592M+6%+14%9%21.1×8.4%+12.0%
Hangzhou AGS MedTech 688581.SSChina$590M-22%-18%33%18.9×0.4%+27.8%
Ningbo David Medical Device 300314.SZChina$589M+25%+19%11%12.0×n/an/a
Orchestra BioMed OBIOUnited States$587M+87%+1,007%-195%n/an/an/a
QuidelOrtho QDELUnited States$657M-20%-5%-2%10.7×n/an/a
Synektik SNT.WAPoland$662M+10%+32%24%13.8×0.2%+47.5%
Shanghai Kinetic Medical 300326.SZChina$662M-10%-28%17%26.0×6.6%-1.9%
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%39.7×n/an/a
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%n/an/an/a
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%33.7×n/an/a
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%n/an/an/a
Shenzhen Sunnypol Optoelectornics 002876.SZChina$680M-9%+29%5%39.0×10.1%+14.2%

Questions

Which companies are Beijing Chunlizhengda Medical Instruments's closest peers?
The cockpit's peer set: Xvivo Perfusion (XVIVO.ST), SunMax Biotechnology (4728.TWO), Nanosonics (NAN.AX), Medistim (MEDI.OL), Sight Sciences (SGHT), Sahajanand Medical Technologies (SMT.NS), AK Medical (1789.HK), vVARDIS (VVVV).
Is Beijing Chunlizhengda Medical Instruments expensive compared with its peers?
On forward p/e it trades at 17.4× against a peer median of 26.0×, 5th cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has Beijing Chunlizhengda Medical Instruments stock performed?
Over six months to 18 Nov 2026 the shares returned -27.4% against -6.6% for the median peer; over one year -55.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.